Evidence map›Paper›PMID 28298291›Full record

ArticleClinical and vaccine immunology : CVI2017

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Qihua Fan, Cody S Nelson, Kristy M Bialas, Flavia Chiuppesi, Joshua Amos, Thaddeus C Gurley, Dawn Jones Marshall, Joshua Eudailey, Holly Heimsath, Jonathon Himes and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Pathogenesis of viral infections during pregnancy.Clinical microbiology reviews · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Qihua FanDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Cody S NelsonDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Kristy M BialasDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Flavia ChiuppesiDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Joshua AmosDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Thaddeus C GurleyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Dawn Jones MarshallDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Joshua EudaileyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Holly HeimsathDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Jonathon HimesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Ashlesha DeshpandeDepartment of Microbiology, University of Alabama, Birmingham, Alabama, USA.
Mark R WalterDepartment of Microbiology, University of Alabama, Birmingham, Alabama, USA.
Felix WussowDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Don J DiamondDepartment of Experimental Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Peter A BarryCenter for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis, California, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Amitinder KaurTulane National Primate Research Center, Tulane University, Covington, Louisiana, USA.
Sallie R PermarDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA sallie.permar@dm.duke.edu.
Duke Medical Center · USCity of Hope · USBeckman Research InstituteUniversity of Alabama at Birmingham · USUniversity of California, Davis · USUniversity of Florida · US

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Peptide Vaccine To Prevent CMV Disease After HSCTR01CA077544 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI DIAMOND, DON J · 1998 to 2017
$5.6M
Evaluation of Protective CMV Vaccines in Rhesus MacaquesR01AI063356 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI BARRY, PETER A, DIAMOND, DON J · 2005 to 2014
$4.6M
CMVPepVax to Protect HCT Recipients from Cytomegalovirus InfectionR01CA181045 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DIAMOND, DON J · 2014 to 2018
$3.6M
Maternal immune protection against congenital CMV infectionDP2HD075699 · NICHD · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2012 to 2017
$2.8M
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast EntryR01AI103960 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BARRY, PETER A, DIAMOND, DON J · 2013 to 2016
$2.8M
Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccinationF30HD089577 · NICHD · DUKE UNIVERSITY · PI NELSON, CODY S · 2017 to 2019
$125k
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077544NCI NIH HHS R01 CA181045NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI063356NIAID NIH HHS R01 AI103960NICHD NIH HHS DP2 HD075699NICHD NIH HHS F30 HD089577NIGMS NIH HHS T32 GM007171NIH HHS P51 OD011104NIH HHS P51 OD011107
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and the leading infectious cause of neurologic deficits and hearing loss in newborns. Development of a maternal HCMV vaccine to prevent vertical virus transmission is a high priority, yet protective maternal immune responses following acute infection are poorly understood. To characterize the maternal humoral immune response to primary CMV infection, we investigated the plasmablast and early antibody repertoire using a nonhuman primate model with two acutely rhesus CMV (RhCMV)-infected animals-a CD4

Indexed as

AnimalsCytomegalovirusCytomegalovirus InfectionsDisease Models, AnimalFemaleInfectious Disease Transmission, VerticalMacaca mulattaPregnancyPregnancy Complications, Infectiouscongenital cytomegalovirusnonhuman primatesvaccine

Identifiers

PMID28298291
PMCPMC5424243
OpenAlexW2605316148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.